Chinese guideline for clinical diagnosis and treatment of malignant pleural mesothelioma (2021 Edition).
10.3760/cma.j.cn112152-20210313-00225
- VernacularTitle:中国恶性胸膜间皮瘤临床诊疗指南(2021版)
- Collective Name:Multidisciplinary Committee of Oncology, Chinese Physicians Association
- Publication Type:Journal Article
- Keywords:
Diagnosis;
Guideline;
Malignant pleural mesothelioma;
Standard;
Therapy
- MeSH:
China;
Humans;
Immunotherapy;
Lung Neoplasms/therapy*;
Mesothelioma/therapy*;
Mesothelioma, Malignant;
Pleural Neoplasms/therapy*
- From:
Chinese Journal of Oncology
2021;43(4):383-394
- CountryChina
- Language:Chinese
-
Abstract:
Malignant pleural mesothelioma (MPM) is a pleura-derived malignant tumor, with a gradually increasing incidence in recent years based on domestic and foreign epidemiologic data. Most patients with MPM are diagnosed at an advanced stage due to its insidiousness and aggressiveness. The therapeutic strategies of MPM mainly include surgery, chemotherapy and radiotherapy. Recently, the immunotherapy has altered the treatment pattern and further improved the survival of these patients. In order to timely present the domestic and foreign progress in the diagnosis and treatment of MPM, and to further improve the level of standardized diagnosis and treatment in MPM in China, this guideline was formulated on the basis of existing clinical research evidence combined with experts' opinions. The guideline covers the epidemiology, diagnosis, pathology, treatment and follow-up of MPM.
